Rituximab, interferon-alfa-2b and dose dense CVP is highly efficient in patients with FLIPI ≥ 2 follicular lymphoma. Final results of the LNH-PRO-05 study

Br J Haematol. 2019 Jul;186(1):168-170. doi: 10.1111/bjh.15760. Epub 2019 Jan 17.
No abstract available

Keywords: follicular lymphoma; interferon; long-term toxicity; survival.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cyclophosphamide / therapeutic use
  • Female
  • Humans
  • Interferon-alpha / therapeutic use*
  • Lymphoma, Follicular / drug therapy*
  • Male
  • Middle Aged
  • Prednisone / therapeutic use
  • Rituximab / therapeutic use*
  • Treatment Outcome
  • Vincristine / therapeutic use

Substances

  • IFNA2 protein, human
  • Interferon-alpha
  • Rituximab
  • Vincristine
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • COP protocol 2